核补充C3b通过在非小细胞肺癌中组装SIN3A/HDAC1/2复合体来促进帕克利塔塞尔耐药性
Xiaochao Wang1, Yan Hao1, Jianfeng Chen2
1Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Cell death & disease
|June 8, 2023
概括
补充成分3 (C3) 通过抑制GADD45A.A.驱动非小细胞肺癌 (NSCLC) 中的帕克利塔塞尔耐药性. 减少C3使耐化学疗的NSCLC细胞变得敏感.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 补体系统,传统上以天生的免疫力而闻名,在T细胞平衡和癌症中扮演着新兴的角色.
- 帕克利塔塞尔 (PTX) 耐药性是非小细胞肺癌 (NSCLC) 治疗的一个主要挑战.
- 补充元件的细胞内功能,特别是补充元件3 (C3),越来越被认可.
研究的目的:
- 调查C3在NSCLC中PTX耐药性的作用.
- 阐明C3赋予PTX耐药性的分子机制.
- 确定C3作为克服NSCLC中PTX耐药性的潜在治疗标.
主要方法:
- 对PTX耐性NSCLC细胞中C3表达的分析.
- C3敲击和子宫外表达的实验.
- 对C3b核转移和与SIN3A复合体相互作用的研究.
- 评估GADD45A表达及其在亡和PTX敏感性中的作用.
主要成果:
- 在抗PTX的NSCLC细胞中,C3的调节显著上升.
- C3 knockdown使抗性细胞对PTX敏感,而C3过度表达会诱导抗性.
- C3b转移到核中,通过HDAC1/2-SIN3A复合体抑制GADD45A的表达.
- 恢复 GADD45A 克服了 PTX 抵抗.
结论:
- 在NSCLC中,C3通过核抑制GADD45A.在PTX耐药性方面发挥了新的致癌作用.
- 准C3或恢复GADD45A可能是提高PTX在耐性NSCLC中的疗效的策略.
- 这项研究揭示了C3在癌症化疗耐药性方面的前所未有的核功能.
相关概念视频
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Anaphase Promoting Complex
2.9K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K


